CHAPEL HILL, N.C.--(BUSINESS WIRE)--Feb. 14, 2007--POZEN Inc.
(NASDAQ:POZN) announced today that it will release fourth quarter and
full year 2006 results on March 7, 2007, before the market opens.
The announcement will be followed by a live webcast at 11:00 a.m.
Eastern Time with a discussion by POZEN management of the financial
and business results. The webcast can be accessed on POZEN's website
at www.pozen.com and will be archived and available for replay. The
fourth quarter and full year 2006 earnings release can be accessed in
the News section of POZEN's website.
POZEN is a pharmaceutical company committed to developing
therapeutic advancements for diseases with unmet medical needs where
it can improve efficacy, safety, and/or patient convenience. POZEN's
efforts are focused primarily on the development of pharmaceutical
products for the treatment of acute and chronic pain and other
pain-related conditions. POZEN has development and commercialization
alliances with GlaxoSmithKline for the proposed product candidate
Trexima(TM) combining sumatriptan, formulated with RT Technology(TM),
and naproxen sodium in a single tablet for the acute treatment of
migraine, which is currently under review by the United States Food
and Drug Administration, and with AstraZeneca for proprietary fixed
dose combinations of the proton pump inhibitor esomeprazole magnesium
with naproxen in a single tablet for conditions such as osteoarthritis
and rheumatoid arthritis in patients who are at risk for developing
NSAID-associated gastric ulcers. The company's common stock is traded
on The Nasdaq Stock Market under the symbol "POZN". For detailed
company information, including copies of this and other press
releases, see POZEN's website: www.pozen.com.
CONTACT: POZEN Inc.
Bill Hodges, Chief Financial Officer, 919-913-1030
Fran Barsky, Director, Investor Relations, 919-913-1044
SOURCE: POZEN Inc.